I don't see & never have the volume here being big pharma swooping in to put it simply they never / or very rarely buy anything on market - they buy at the table. Who I do see buying though is sector specific funds or VC's that's their place and already being well aware of how & where Patrys stood on value then the triggers firstly orphan designation by the FDA & then today's update on trials in combination with Kyprolis - Onyx/Amgen - it opens the table up & the aforementioned can see that. If they think they can broker a big deal out of this they are all over it. Patrys has just ticked the right boxes to initiate on table maybe not today or next week but if they can see it over the next 6 months they'll be all over it to build a weighted interest and walk it through.
PAB Price at posting:
8.0¢ Sentiment: None Disclosure: Held
